Highly active HIV antibody restricts development of viral resistance

by German Center for Infection Research(left to right): Henning Gruell, Philipp Schommers and Florian Klein. Credit: Uniklinik Koeln/Thies SchoeningAntiretroviral drugs are the gold standard for the t

Updated on: April 16,2024 19

Highly active HIV antibody restricts development of viral resistance

by German Center for Infection Research(left to right): Henning Gruell, Philipp Schommers and Florian Klein. Credit: Uniklinik Koeln/Thies SchoeningAntiretroviral drugs are the gold standard for the t

Updated on:April 16,2024 19

Simple blood test could predict risk of long-term COVID-19 lung problems

by University of VirginiaComputerized tomography images of Early- and Late- Resolving COVID associated pulmonary fibrosis and study design. (A) CT images of two COVID survivors displaying resolvi

Updated on: March 19,2024 19

Simple blood test could predict risk of long-term COVID-19 lung problems

by University of VirginiaComputerized tomography images of Early- and Late- Resolving COVID associated pulmonary fibrosis and study design. (A) CT images of two COVID survivors displaying resolvi

Updated on:March 19,2024 19

How a novel drug pushes the HIV capsid to breaking point

by University of New South WalesLenacapavir causes the HIV capsid to rupture before it can transport its genetic material to the host cell nucleus. Credit: Public Health Image Library, CDCJust ov

Updated on: June 04,2024 3

How a novel drug pushes the HIV capsid to breaking point

by University of New South WalesLenacapavir causes the HIV capsid to rupture before it can transport its genetic material to the host cell nucleus. Credit: Public Health Image Library, CDCJust ov

Updated on:June 04,2024 3

A simple T-cell test to show the full picture of body's immune response to COVID-19

by Duke-NUS Medical SchoolGraphical abstract. Credit: DOI: 10.1172/JCI152379Researchers from Duke-NUS Medical School, together with collaborators from the National Centre for Infectious Diseases

Updated on: March 26,2024 11

A simple T-cell test to show the full picture of body's immune response to COVID-19

by Duke-NUS Medical SchoolGraphical abstract. Credit: DOI: 10.1172/JCI152379Researchers from Duke-NUS Medical School, together with collaborators from the National Centre for Infectious Diseases

Updated on:March 26,2024 11

Lolamicin: A Revolutionary Antibiotic Targeting Gram-Negative Bacteria Without Disrupting the Gut Microbiome

Updated on: June 01,2024 0

Lolamicin: A Revolutionary Antibiotic Targeting Gram-Negative Bacteria Without Disrupting the Gut Microbiome

Updated on:June 01,2024 0

Why has October been so bad for a virus known as RSV?

by Harriet Blair RowanCredit: Pixabay/CC0 Public DomainOctober is usually a quiet month for Dr. Julie Kim and her colleagues at their pediatrics practice in Los Gatos, after the summer rush for physic

Updated on: June 08,2024 3

Why has October been so bad for a virus known as RSV?

by Harriet Blair RowanCredit: Pixabay/CC0 Public DomainOctober is usually a quiet month for Dr. Julie Kim and her colleagues at their pediatrics practice in Los Gatos, after the summer rush for physic

Updated on:June 08,2024 3

Vaccine to prevent a dangerous tropical disease receives approval

by Estonian Research CouncilWork in Tartu University's virology lab. Author Kaspar Koolmeister. Credit: Kaspar KoolmeisterThe chikungunya virus is widespread in tropical regions, where it is sprea

Updated on: May 05,2024 18

Vaccine to prevent a dangerous tropical disease receives approval

by Estonian Research CouncilWork in Tartu University's virology lab. Author Kaspar Koolmeister. Credit: Kaspar KoolmeisterThe chikungunya virus is widespread in tropical regions, where it is sprea

Updated on:May 05,2024 18

Antibody production in patients hospitalized with COVID-19

by Mary Ann Liebert, IncCredit: Mary Ann Liebert, Inc., publishersAntibody-secreting cells (ASCs) peaked at 3-4 weeks and were still being produced at 3-4 months in patients hospitalized with COV

Updated on: April 12,2024 20

Antibody production in patients hospitalized with COVID-19

by Mary Ann Liebert, IncCredit: Mary Ann Liebert, Inc., publishersAntibody-secreting cells (ASCs) peaked at 3-4 weeks and were still being produced at 3-4 months in patients hospitalized with COV

Updated on:April 12,2024 20

Gilead licenses HIV-prevention drug to generic drugmakers

Credit: Pixabay/CC0 Public DomainUS pharmaceutical giant Gilead said Wednesday it had signed licensing deals with six generic drugmakers to produce and sell its HIV prevention medicine in lower-income

Updated on: October 21,2024 0

Gilead licenses HIV-prevention drug to generic drugmakers

Credit: Pixabay/CC0 Public DomainUS pharmaceutical giant Gilead said Wednesday it had signed licensing deals with six generic drugmakers to produce and sell its HIV prevention medicine in lower-income

Updated on:October 21,2024 0

How SARS-CoV-2 defeats the innate immune response

byKobe UniversityA section of Goodsell et al.'s magnificent "Integrative illustration for coronavirus outreach" highlighting the packaging of the viral genetic material (in pink) b

Updated on: November 15,2024 0

How SARS-CoV-2 defeats the innate immune response

byKobe UniversityA section of Goodsell et al.'s magnificent "Integrative illustration for coronavirus outreach" highlighting the packaging of the viral genetic material (in pink) b

Updated on:November 15,2024 0

Fibrinolytic biomarkers for identifying patients at risk of severe COVID-19

by Juntendo University Research Promotion CenterSignificant decreases in circulating uPA and uPA/PAI-1 complex levels may be a novel biomarker of COVID-19 severity. Credit: Dr. Koichi Hattori/Juntendo

Updated on: March 20,2024 11

Fibrinolytic biomarkers for identifying patients at risk of severe COVID-19

by Juntendo University Research Promotion CenterSignificant decreases in circulating uPA and uPA/PAI-1 complex levels may be a novel biomarker of COVID-19 severity. Credit: Dr. Koichi Hattori/Juntendo

Updated on:March 20,2024 11

A new class of antibodies against COVID-19 is being put to the test

by Garvan Institute of Medical ResearchStructural characterization of the broadly neutralizing class 1 antibody GAR05. a Cryo-EM structure of GAR05 Fab bound to trimeric spike (3.27 Å resolution)

Updated on: March 25,2024 11

A new class of antibodies against COVID-19 is being put to the test

by Garvan Institute of Medical ResearchStructural characterization of the broadly neutralizing class 1 antibody GAR05. a Cryo-EM structure of GAR05 Fab bound to trimeric spike (3.27 Å resolution)

Updated on:March 25,2024 11